You have read all your free articles, to continue reading subscribe to read the rest of this content.
The Norwegian biotech company has announced the appointment of Namir Hassan as chief scientific officer (CSO). “Namir has gathered extensive scientific knowledge in immunology, and, specifically, T-cell receptor based therapies. His experience spans research through to translational developmentAlready a subscriber Login You have read all your free articles, to continue…
The company has announced the appointment of its current Chairman Torbjørn Bjerke as its new Chief Executive Officer, effective as from the Annual General Meeting to be held on May 25. Torbjørn Bjerke succeeds Jeppe Øvlesen, who will remain a committed shareholder of the company. The NominatioAlready a subscriber Login…
Abliva has announced that the Board of Directors, in agreement with Erik Kinnman, the current CEO, has appointed Ellen K. Donnelly as the company’s new CEO. Ellen K. Donnelly will lead Abliva’s development into a commercial biopharmaceutical company. She succeeded Erik Kinnman, around FebruarAlready a subscriber Login You have read…
As part of its Expand and Invest to Grow-strategy, Lundbeck plans to make changes to its organization in Research & Development (R&D). The initiative could lead to a reduction of around 130-160 positions globally (subject to consultation), including approximately 100 in Denmark. “ThAlready a subscriber Login You have read all your…
